Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ribavirin Litigation Set To Rest: Valeant's Appeal In Patent Case Dismissed

This article was originally published in The Pink Sheet Daily

Executive Summary

Valeant requested the dismissal. The company's appeal was largely premised on FDA approval of a citizen petition concerning ribavirin generics' ability to "carve out" protected labeling; the agency denied the petition in April.

You may also be interested in...

Schering Generic Ribavirin Carries PEG-Intron Indication; Valeant Will Receive Royalties

Schering generic launches April 8, two days after FDA clears Three Rivers’ and Sandoz’ ribavirin ANDAs. All generics are expected to be priced at a 10% discount to Schering’s Rebetol.

Three Rivers/Par, Sandoz Ribavirin ANDAs Approved By FDA; Companies Will Share Exclusivity

Three Rivers/Par launch Ribasphere at a 10% discount to Schering-Plough’s Rebetol. The generics are approved for use in combination with interferon alfa-2b for the treatment of hepatitis C.

Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint

FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts